

GILEAD SCIENCES INC  
Form 8-K  
July 20, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

July 20, 2006

---

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**0-19731**  
(Commission File Number)

**94-3047598**  
(I.R.S. Employer  
Identification No.)

**333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA**

(Address of principal executive offices)

**94404**

(Zip Code)

**(650) 574-3000**

(Registrant's telephone number, including area code)

## Edgar Filing: GILEAD SCIENCES INC - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**SECTION 2 FINANCIAL INFORMATION**

**Item 2.02 Results of Operations and Financial Condition**

On July 20, 2006, Gilead Sciences, Inc., a Delaware corporation (the Company), issued a press release announcing the financial results for the quarter ended June 30, 2006. A copy of the press release is filed as Exhibit 99.1 to this report.

Each non-GAAP financial measure reflected in the earnings press release is included because the Company's management uses this information to better understand the comparative operating performance of the Company. For the three months ended June 30, 2006, these adjustments included \$27.7 million of after-tax stock based compensation expense from the impact of our adoption of the Financial Accounting Standards Board's Statement No. 123 (revised 2004), Share Based Payment. Consequently, excluding these transactions from the Company's results provides users of the financial statements an important insight into the Company's results and related trends that affect the Company's core business.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS**

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, issued by Gilead Sciences, Inc. on July 20, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GILEAD SCIENCES, INC.**  
(Registrant)

/s/ John F. Milligan  
John F. Milligan

Executive Vice President and

Chief Financial Officer

Date: July 20, 2006

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, issued by Gilead Sciences, Inc. on July 20, 2006